Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Novartis Ag patents


Recent patent applications related to Novartis Ag. Novartis Ag is listed as an Agent/Assignee. Note: Novartis Ag may have other listings under different names/spellings. We're not affiliated with Novartis Ag, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "N" | Novartis Ag-related inventors


 new patent  Methods of improving or accelerating physical recovery after surgery for hip fracture

. . The disclosure relates to novel uses and regimens for accelerating/improving physical recovery in a patient with disuse atrophy triggered by reduced mobility due to a hip fracture and consequent major surgery, which employ a therapeutically effective amount of a myostatin antagonist, e.g., a myostatin binding molecule, e.g., a myostatin antibody or an actrii receptor binding molecule, an actrii receptor antibody, such as the bimagrumab antibody.. . ... Novartis Ag

 new patent  Surgical guidance and planning software for astigmatism treatment

Software for calculating an astigmatism treatment is operable upon execution to perform the following steps: receiving biometric information for a patient; determining based on the biometric information an astigmatic correction comprising at least one of (a) a position for one or more limbal relaxing incisions and (b) a power and an orientation for a toric intraocular lens (iol); generating an output comprising the astigmatic correction; receiving a selection of a different ratio of astigmatic correction attributable to the one or more limbal relaxing incisions and the toric iol; determining an updated astigmatic correction including at least one of (a) an updated position for the one or more limbal relaxing incisions and (b) an updated power and/or orientation of the toric iol.. . ... Novartis Ag

Gdf-15 as a haematological toxicity biomarker

The present disclosure relates to use of gdf-15 as a safety biomarker for determining a toxicological effect of a mdm2 inhibitor; an ex vivo method for determining a toxicological effect of a mdm2 inhibitor in a subject, in particular for determining a likelihood of developing thrombocytopenia in a subject in response to administration of a dose of a mdm2 inhibitor; methods of using a mdm2 inhibitor in the treatment of cancer in a subject; a kit for use in predicting the likelihood that a patient having cancer will develop thrombocytopenia in response to a treatment with a dose of a mdm2 inhibitor; a kit for use in treating a patient having cancer and related disclosure embodiments.. . ... Novartis Ag

Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer

The present application n relates to a pharmaceutical composition comprising a pd-1 antibody and an m-csf antibody. The combination can be administered independently or separately, in a quantity which is therapeutically effective for the treatment of cancer.. ... Novartis Ag

Combination therapy

Reversing resistance to a b-raf inhibitor for the treatment of a proliferative disease by obtaining a tumor sample from the patient and testing it for genetic alterations in a panel of genes comprising braf, craf, ccnd1, cdk4, her2, igf-1r, cmet, fgfr1, fgfr2, fgfr3 egfr, map2k1, map2k2, nras, kras hras, pten, pik3ca, and p16 and administering a drug combination therapy comprising the b-raf inhibitor and a second inhibitor which overcomes resistance to the b-raf inhibitor, which second inhibitor is selected based on genetic alterations discovered in the tumor sample.. . ... Novartis Ag

Oral formulations of deferasirox

Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral ph or at neutral ph.. . ... Novartis Ag

Systems and method for augmented reality ophthalmic surgical microscope projection

The disclosure provides a system including an augmented reality device communicatively coupled to an imaging system of an ophthalmic microscope. The augmented reality device may include a lens configured to project a digital image, a gaze control configured to detect a focus of an eye of an operator, and a dimming system communicatively coupled to the gaze control and the outer surface and including a processor that receives a digital image from the imaging system, projects the digital image on the lens, receives a signal from the gaze control regarding the focus of the eye of the operator, and transitions the outer surface of the augmented reality device between at least partially transparent to opaque based on the received signal. ... Novartis Ag

Combination

The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering n-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6.7-tetrahydro-2h-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and n-[(1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl]-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, to a human in need thereof.. ... Novartis Ag

Pharmaceutical compositions comprising 40-o-(2-hydroxy)ethyl-rapamycin

The invention relates to extended release pharmaceutical formulations in form of multiparticulates comprising 40-o-(2-hydroxy)ethyl-rapamycin, to dosage forms which comprise said pharmaceutical formulations, to methods of preparing said pharmaceutical formulations and said dosage forms, to uses of said pharmaceutical formulations and said dosage for the manufacture of a medicament for the treatment or prevention of diseases or conditions responsive to inhibition of mtor signaling pathway, such as for instance proliferative diseases or immunosuppression.. . ... Novartis Ag

System and method for cutting a flap using polarization sensitive optical coherence tomography

The present disclosure provides a system and method for cutting a flap in laser ophthalmic surgery using polarization sensitive optical coherence tomography (ps-oct). The system includes a ps-oct system, a femtosecond laser, control device, and processor. ... Novartis Ag

Mechanical optics for mixed mode surgical laser illumination

Mechanical optics for mode mixing may be used to homogenize different modes in an optical fiber used for surgical illumination. A mechanical optical element, such as a rotating prism or a mirror membrane, may impart motion to an incident beam entering the optical fiber to generate a homogeneous illumination field from a coherent light source.. ... Novartis Ag

Focusing optics for mixed mode surgical laser illumination

Focusing optics for mode mixing may be used to homogenize different modes in an optical fiber used for surgical illumination. A vibration stage may impart mechanical motion to a condenser lens to generate a homogeneous illumination field from a coherent light source.. ... Novartis Ag

Fiber-based mode mixing techniques for surgical laser illumination

Fiber-based mode mixing techniques may be used to homogenize different modes in an optical fiber used for surgical illumination. A vibrating fiber mechanism may impart mechanical motion to a portion of the optical fiber to generate a homogeneous illumination field from a coherent light source.. ... Novartis Ag

Frequency-based mode mixing for surgical laser illumination

Frequency-based mode mixing may be used to homogenize different modes in an optical fiber used for surgical illumination. A laser modulator may introduce frequency modulation to laser light to generate a homogeneous illumination field due to increased mode mixing in the optical fiber.. ... Novartis Ag

08/02/18 / #20180214019

Ophthalmic surgical image processing

A system and method for ophthalmic surgery in which a portion of the light reflected by the eye passes through a lens that inverts the image and a portion of the light reflected by the eye does not pass through the lens. A digital image of both light that passed through the lens (lens image) and light that has not (peripheral image) is created using an image sensor. ... Novartis Ag

08/02/18 / #20180214018

Pixelated array optics for mixed mode surgical laser illumination

Pixelated array optics for mode mixing may be used to homogenize different modes in an optical fiber used for surgical illumination. A pixelated phase array, such as a digital micromirror device or an lcd phase plate, may impart motion to an incident beam entering the optical fiber to generate a homogeneous illumination field from a coherent light source.. ... Novartis Ag

07/26/18 / #20180209778

Dynamic mode switching for multi-mode ophthalmic optical coherence tomography

Techniques and apparatus for selectively producing half-depth and full-depth oct images, based on a swept-source oct interference signal. An example method comprises selecting from a first sampling rate and a second sampling rate, the second sampling rate being twice the first sampling rate, and sampling the swept-source optical coherence tomography (oct) interference signal at the selected sampling rate, using a k-clock signal having a frequency range corresponding to the first sampling rate, to produce a sampled oct interference signal. ... Novartis Ag

07/26/18 / #20180207330

On-demand fluidics system control based on frequency-domain processing

Frequency-domain signal processing of pressure sensor signals and/or flow signals is used to provide on-demand control of a multi-component fluidic system. An example method, implemented in a phacoemulsification system comprises receiving a signal from each of one or more sensors, the one or more sensors comprising at least one pressure sensor, and converting each of one or more of the received signals, including at least one signal from a pressure sensor, to a frequency-domain representation of the received signal. ... Novartis Ag

07/26/18 / #20180207163

Methods and compositions for treating solid tumors and other malignancies

A combination of a cdk4/6 inhibitor and an mtor inhibitor for the treatment of cancer.. . ... Novartis Ag

07/26/18 / #20180207128

Immunosuppressant formulation

The present invention concerns a dosage form, preferably for immediate release, comprising siponimod, a moisture-protective-agent and further pharmaceutical excipients and methods for producing said dosage form.. . ... Novartis Ag

07/26/18 / #20180207033

System and method for reducing post-surgical rainbow effect

The disclosure relates to a pulsed laser system including a laser source that generates a laser beam, a scanner that controls the location of a beam focal point of the laser beam and also the location of a photodisruption formed at the beam focal point in a cornea of an eye, a computer that generates instructions to the laser source and scanner to direct the formation of a regular photodisruption pattern in the cornea, and a noise source that disturbs the location of each photodisruption to cause an irregular photodisruption pattern to form in the cornea, such that diffraction of light by the cornea after formation of the photodisruption pattern is decreased or avoided.. . ... Novartis Ag

07/26/18 / #20180207032

Vacuum control for a vitrectomy probe

Vitrectomy probes and methods related thereto are disclosed herein. A vitrectomy probe may include a hand piece comprising a housing, a venturi, a piloted proportional valve disposed in the housing, and aspiration tubing fluidly coupled to the piloted proportional valve. ... Novartis Ag

07/26/18 / #20180206874

Vitrectomy probe with integral valve

A vitrectomy apparatus for performing an ocular surgery may include a vitrectomy probe body graspable by a user and a cutter extending from the body and comprising an inner tube and an outer tube. The inner tube may be moveable relative to the outer tube. ... Novartis Ag

07/19/18 / #20180201674

Methods of using il-1beta compounds

. . This invention relates to methods employing il-1 beta-ligand/il-1 receptor disrupting compounds, such as il-1 beta antibodies or il-1 receptor antibodies, in the treatment and/or prevention of auto-inflammatory syndromes in mammals, particularly humans.. . ... Novartis Ag

07/19/18 / #20180200218

Inhibitors for treating diseases characterized by atrial enlargement or remodeling

The present invention relates to the nep inhibitor pro-drug n-(3-carboxy-1-oxopropyl)-(4s)-p-phenylphenylmethyl)-4-amino-(2r)-methylbutanoic acid ethyl ester, or a pharmaceutically acceptable salt thereof; or the nep inhibitor n-(3-carboxy-1-oxopropyl)-(4s)-p-phenylphenylmethyl)-4-amino-(2r)-methylbutanoic acid, or a pharmaceutically acceptable salt thereof, pro-drug for use in the treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling; a method for treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of the nep inhibitor or the nep inhibitor pro-drug, or a pharmaceutically acceptable salt pro-drug thereof, to a subject, e.g. A human subject, in need of such treatment. ... Novartis Ag

07/19/18 / #20180200109

Surgical handpiece with reverse flow priming

A method and system provide a surgical handpiece including a housing and a horn. The housing has a retrograde channel and a chamber a therein. ... Novartis Ag

07/19/18 / #20180200047

Intraocular lens injector

Apparatuses, systems, and methods for implanting an intraocular lens into an eye are described. For example, an intraocular lens injector may include a passage formed in a distal end portion of the intraocular lens injector. ... Novartis Ag

07/19/18 / #20180200046

Intraocular lens injector

Apparatuses, systems, and methods for implanting an intraocular lens into an eye are described. For example, an intraocular lens injector may include a passage formed in a distal end portion of the intraocular lens injector. ... Novartis Ag

07/19/18 / #20180199812

Calibration method for a camera-based measuring device for diagnosis of a human eye

A calibration method for a camera-based measuring device comprises positioning a calibration object simulating an anterior region of the eye on a holder arranged movably in a first direction relative to a camera of the measuring device within a view field of the camera. The first direction is toward and away from the camera substantially along a camera axis. ... Novartis Ag

07/19/18 / #20180199809

Method and apparatus for optical coherence tomography scanning

A method and system provide an optical coherence tomography system including a light source, an interferometric system, a processor and a memory. The interferometric system is optically coupled with the light source and includes at least one movable scanning mirror. ... Novartis Ag

07/12/18 / #20180194846

Compositions and methods for increasing muscle growth

. . This disclosure is in the field of anti-activin receptor iib (actriib) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.. ... Novartis Ag

07/12/18 / #20180194839

Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders

The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine il-17 a. The disclosure more specifically relates to specific antibodies and proteins that are il-17 a antagonists (inhibit the activities of il-17 a and il-17 af) and are capable of inhibiting il-17 a induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo. ... Novartis Ag

07/12/18 / #20180194835

Use of vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients

The present invention relates to the use of a vegf antagonist in the treatment of chorioretinal neovascular or permeability disorders in children. In particular, the invention provides a vegf antagonist for use in a method for treating a child having cnv or me, wherein said method comprises administering to the eye of a child a vegf antagonist that either does not enter or is rapidly cleared from the systemic circulation. ... Novartis Ag

07/12/18 / #20180194823

Peptides and compositions for treatment of joint damage

The present invention provides new protease resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.. . ... Novartis Ag

07/12/18 / #20180193475

Ckit antibody drug conjugates

The present invention relates to anti-ckit antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.. . ... Novartis Ag

07/12/18 / #20180193346

Pharmaceutical combinations

The disclosure relates to a pharmaceutical combination of a mdm2/4 inhibitor, namely (s)-1-(4-chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2h-isoquinolin-3-one or (s)-5-(5-chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1h-pyrrolo[3,4-d]imidazol-4-one, and a cyclin dependent kinase 4/6 (cdk4/6) inhibitor 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide. In addition, the disclosure relates to a pharmaceutical combination product. ... Novartis Ag

07/12/18 / #20180193192

Systems and methods for pressure-driven tool actuation

The present disclosure describes systems and methods for pressure-driven micro-surgical tool actuation. The systems and methods may encompass the use of a remote handle held by a first hand of a user as well as a surgical tool located in the eye of a patient. ... Novartis Ag

07/12/18 / #20180192871

Ophthalmic surgery using light-field microscopy

A system and method for ophthalmic surgery in which a light field camera is used to capture a digital image of the surgical field including the eye. The digital image is used to create image information and directional information, which is then used to from a three dimensional (3d) image with motion parallax.. ... Novartis Ag

07/05/18 / #20180186802

Compounds and compositions as toll-like receptor 7 agonists

The invention provides compounds of formula (i), immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with toll-like receptor 7 activity.. . ... Novartis Ag

07/05/18 / #20180185365

Pharmaceutical combinations

A pharmaceutical combination comprising (a) an alk inhibitor, or a pharmaceutically acceptable salt thereof, and (b) at least one hdma-2/p53 receptor inhibitor or a pharmaceutically acceptable salt, or at least one braf inhibitor or a pharmaceutically acceptable salt, and optionally a pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of cancer; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.. . ... Novartis Ag

07/05/18 / #20180185341

Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors

The present invention relates to therapeutic uses of compounds of formula (i) or a pharmaceutically acceptable salt thereof. . ... Novartis Ag

06/28/18 / #20180179290

Antibody formulation

Anti-baffr antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. ... Novartis Ag

06/28/18 / #20180179181

Protein kinase c inhibitors and methods of their use

Pkc inhibitors are disclosed. The pkc inhibitors are useful for treating pkc associated diseases, including certain cancers. ... Novartis Ag

06/28/18 / #20180177747

Paediatric compositions for treating multiple sclerosis

The present invention relates to pharmaceutical compositions comprising a 2-amino-2-[2-(4-c2-20- alkyl-phenyl)ethyl]propane-1,3-diol compound or a pharmaceutically acceptable salt thereof, and to the use thereof for treating, preventing or delaying the progression of multiple sclerosis in a paediatric patient or a patient suffering from a specific condition.. . ... Novartis Ag

06/21/18 / #20180172971

Systems and methods for active vibration reduction of a surgical microscope

. . The present disclosure provides a system for active vibration reduction of a surgical microscope. The system includes a surgical microscope with an optical head connected to a control device that adjusts the position of the optical head in any of the x, y, and z-directions. ... Novartis Ag

06/21/18 / #20180171005

Compositions and methods for antibodies targeting bmp6

The present invention relates to antibodies and antigen-binding fragments thereof to human bmp6 and compositions and methods of use thereof.. . ... Novartis Ag

06/21/18 / #20180170917

Compounds and compositions as raf kinase inhibitors

The present invention provides compounds of formula (i) and (ii) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.. ... Novartis Ag

06/21/18 / #20180170887

Novel heteroaryl butanoic acid derivatives

The present invention describes novel heteroaryl butanoic acid derivatives that are good drug candidates especially with regard to leukotriene a4 hydrolase (lta4h). The present invention also relates to pharmaceutical compositions comprising said novel heteroaryl butanoic acid derivatives, methods of using said compounds in the treatment of various diseases and disorders, and processes for preparing the said novel compounds.. ... Novartis Ag

06/21/18 / #20180169981

Method for producing contact lenses

The invention provides a method producing contact lenses, comprising the step of: separating the mold into the male and female mold halves, with the silicone hydrogel contact lens adhered on one of the male and female mold halves; bring a shaped ultrasonic horn in direct contact with at least one area of a non-optical surface of the female mold half or the male mold half having the molded silicone hydrogel contact lens attached thereon; and applying a ultrasonic vibrational energy to the at least one area of the non-optical surface of the female mold half or the male mold half having the molded silicone hydrogel contact lens attached thereon so as to separate the molded silicone hydrogel contact lens from the mold half attached thereon.. . ... Novartis Ag

06/21/18 / #20180169246

Anti-cd40 antibody formulation

Anti-cd40 antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. ... Novartis Ag

06/21/18 / #20180169225

Methods for preparing squalene

An improved method for preparing squalene from a squalene-containing composition, said method comprising the steps of (a) a purification distillation carried out at a temperature t1 (b) a denaturing distillation carried out at a temperature t2; wherein steps (a) and (b) may be performed in either order; t1 and t2 are sufficient to cause squalene to boil; t2>t1; and t2>200° c.. . ... Novartis Ag

06/21/18 / #20180168861

Illuminated surgical probe having a variable illumination numerical aperture

A surgical probe system comprising a surgical probe having a probe needle, an optical fiber incorporated onto the probe needle, wherein a proximal end of the optical fiber is connected to a light source and a distal end of the optical fiber projects illumination light from the light source over a tip of the probe needle; and an adjustment mechanism that varies the illumination light between a first beam having a first numerical aperture that facilitates vitreous visualization and a second beam having a second numerical aperture that facilitates background illumination, wherein the second numerical aperture is larger than the first numerical aperture.. . ... Novartis Ag

06/21/18 / #20180168768

Illuminated surgical probe having multiple optical fibers

A surgical probe system comprising a surgical probe having a probe needle, a first optical fiber incorporated onto the probe needle, wherein a distal end of the first optical fiber projects a first beam of illumination light over a tip of the probe needle when activated; a second optical fiber incorporated onto the probe needle, wherein a distal end of the second optical fiber projects a second beam of illumination light over the tip of the probe needle when activated; and a third optical fiber incorporated onto the probe needle, wherein a distal end of the third optical fiber projects a third beam of light over the tip of the probe needle to perform a distance measurement between the probe needle and a patient's when activated, wherein the distance measurement is displayed or audibly presented to aid a user in probe positional awareness with respect to the patient's retina.. . ... Novartis Ag

06/21/18 / #20180168737

Adaptive image registration for ophthalmic surgery

An ophthalmic surgical system includes a first imaging system configured to generate a first image of an eye, a second imaging system configured to generate a second image of the eye, and an image registration system comprising a processor and instructions stored on a memory, the instructions executable by the processor to cause the image registration system to receive the first image generated by the first imaging system, receive the second image generated by a second imaging system, track a location of a distal tip of a surgical instrument in the first image, define a priority registration region in the first image, the priority registration region comprising a portion of the first image within a predetermined proximity of the distal tip of the surgical instrument, register the priority registration region in the first image with a corresponding region in the second image, and update the registration of the priority registration region in the first image with the corresponding region in the second image in real time as the distal tip is moved, without registering portions of the first or second images that are outside the registration regions.. . ... Novartis Ag

06/21/18 / #20180168445

Systems and methods for wide field-of-view optical coherence tomography

An optical coherence tomography (oct) system includes a light source configured to generate an oct beam and a beam splitter, configured to split the oct beam into a reference beam and an imaging beam, direct the reference beam toward a reflector, and direct the imaging beam toward a scanner. The system includes a linear actuator, such as a piezoelectric or voice coil, configured to move the reflector to adjust the length of the reference beam and the scanner, configured to scan the imaging beam onto a target surface at a plurality of scan angles, wherein the scanner and target surface are separated by a sample distance that varies at each of the scan angles. ... Novartis Ag

06/14/18 / #20180162570

Apparatus for sealing an ophthalmic lens package

. . An apparatus for thermally bonding together a cover film of an ophthalmic lens package and a base part of the package, including a carrier for supporting the base part with film arranged thereon; a bonding unit above the carrier having a mounting plate with a bonding stamp extending therefrom, the bonding stamp having a mounting portion fixedly attached to the mounting plate, a bonding head arranged beneath the mounting portion with a heatable bonding contour on a side of the bonding head facing the carrier, and an articulated connector arranged between and connecting the mounting portion and the bonding head; and an actuator for performing movement of the carrier and the bonding stamp towards and away from each other for thermally bonding the film with the base part by pressing the heated bonding contour against the film and subsequent separation of the bonding head from the cover film bonded to the base part, the articulated connector being a cardanic joint with two rotational axes.. . ... Novartis Ag

06/14/18 / #20180161319

Methods of enhancing immune response

The present invention relates to a method of enhancing immune response in a subject.. . ... Novartis Ag

06/14/18 / #20180161280

Pharmaceutical compositions comprising everolimus

The invention relates to a pharmaceutical formulation comprising 40-o-(2-hydroxy)ethyl-rapamycin in a high drug load part and an immediate release part. In addition, the invention relates to a formulation comprising 40-o-(2-hydroxy)ethyl-rapamycin in a first layer and a surfactant in a layer beneath the first layer. ... Novartis Ag

06/14/18 / #20180160900

Collapsible surgical mirror for intraocular visualization

The present disclosure provides a small gauge extendable-retractable mirror for use in intraocular surgery. The mirror of the present disclosure can be used in intraocular surgery to enable visualization of areas of the eye currently difficult or impossible to view, such as, e.g., behind the iris.. ... Novartis Ag

06/07/18 / #20180153899

Pharmaceutical compositions

. . Pharmaceutical compositions comprising the drug substance (r,e)-n-(7-chloro-1-(1-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-1h-benzo[d]imidazol-2-yl)-2-methylisonicotinamide and processes to prepare these compositions.. . ... Novartis Ag

06/07/18 / #20180153861

Method of treating atherosclerosis in high triglyceride subjects

The present invention provides a compound of formula i for use in the treatment, amelioration and/or prevention of diseases and conditions associated with cetp activity, such as atherosclerosis and dyslipidemia, in a subject with high triglyceride level; wherein r1, x1, r7, r5, c, l and p are defined herein. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of diseases and conditions associated with cetp activity, such as atherosclerosis and dyslipidemia, in a subject with high triglyceride levels.. ... Novartis Ag

05/31/18 / #20180149467

Visualization systems and methods for optimized optical coherence tomography

The present disclosure provides a visualization system for performing optimized optical coherence tomography (oct) by determining the absolute distance between the oct source and a sample. The present disclosure also provides a method for optimizing oct, which includes determining an absolute distance between the oct source and a sample using data relating to the focal length or position of an autofocus imager lens.. ... Novartis Ag

05/31/18 / #20180149464

Automated optical coherence tomography scanning

An optical coherence tomography (oct) system and method for scanning a defined area according to a pre-set or user-specified scanning pattern, the defined area surrounding a specified starting position or offset from the starting position. Such oct systems and methods may be used to generate a pictorial representation of internal target structures the oct sample beam passed through.. ... Novartis Ag

05/31/18 / #20180147087

System and method for monitoring phototoxicity during ophthalmic surgery

The present disclosure provides a system and method for monitoring phototoxicity caused by vitreous visualization device (“vvd”) illumination during ophthalmic surgery. The systems and methods determine the cumulative amount of optical energy incident on the retina, which corresponds to phototoxicity, the distance between a cutter of the vvd and the retina, and areas where the vitreous has been removed, or any combination thereof. ... Novartis Ag

05/31/18 / #20180147052

Intraocular lenses having zone-by-zone step height control

A method and system provide an ophthalmic device. The ophthalmic device includes an ophthalmic lens having anterior surface, a posterior surface and at least one diffractive structure including a plurality of zones. ... Novartis Ag

05/31/18 / #20180147050

Multifocal lens having reduced chromatic aberrations

A method and system provide a multifocal ophthalmic device. The ophthalmic lens has an anterior surface, a posterior surface and at least one diffractive structure including a plurality of echelettes. ... Novartis Ag

05/24/18 / #20180141293

Method for making ophthalmic lenses

. . Described herein is a cost-effective and time-efficient method for making contact lenses having a hydrophilic surface and a reduced uptake of cationic compounds, e.g. From care solutions. ... Novartis Ag

05/24/18 / #20180140662

Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers

The present invert on relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two or more different polylactide-co-glycolide polymers (plgas).. . ... Novartis Ag

05/24/18 / #20180140579

Sacubitril and valsartan for treating metabolic disease

The present invention relates to methods and pharmaceutical compositions for prevention or treatment of a metabolic disease in a human patient in need thereof, comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of a combination of sacubitril and valsartan in a 1:1 molar ratio to said patient.. . ... Novartis Ag

05/24/18 / #20180140374

Ophthalmic illumination systems, devices, and methods

Systems, apparatuses, and methods of and for an ophthalmic illumination system are disclosed. In an exemplary implementation, an ophthalmic illumination system includes a collimator having at least one lens. ... Novartis Ag

05/24/18 / #20180140373

Vitreous visualization system and method

The present disclosure provides a vitreous visualization system including a vitreous illuminator including a vitreous visualization light source and a vitreous visualization tool that transmits lights from the vitreous visualization light source into an eye having vitreous, a pupil, and a vitreous-pupil axis. The vitreous visualization system further includes a general illuminator, which may include a general light source and a general illumination tool that transmits light from the general light source into the eye. ... Novartis Ag

05/24/18 / #20180140189

Contact lens mounting speculum for vitreoretinal surgery

A contact lens is placed on a patient's eye during ophthalmic surgery, such as vitreoretinal surgery. The contact lens rests on a cornea of an eye of a patient during the surgery and is supported by a contact lens mounting speculum having multiple degrees of freedom to accommodate small movements of the eye while enabling alignment to an optical axis of the surgical microscope. ... Novartis Ag

05/24/18 / #20180140179

Systems and methods using a vitreous visualization tool

The present disclosure provides a vitreous visualization system including a general light source, a general conduit that transmits light from the general light source through a conduit portion of a general illumination optical fiber, and a combined vitreous visualization and general illumination tool that receives light from the general conduit. The combined vitreous visualization tool includes a vitreous visualization light source, a controller for the vitreous visualization light source, a vitreous visualization optical fiber, a tool portion of the general illumination optical fiber, and a probe tip through which at least parts of both the vitreous visualization optical fiber and the tool portion of the general illumination optical fiber pass.. ... Novartis Ag

05/17/18 / #20180133226

Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor

. . The invention relates to a pharmaceutical combination which comprises (a) a phosphoinositide 3-kinase inhibitor compound of formula (i) and (b) a mtor inhibitor for the treatment of a target of rapamycin (mtor) kinase dependent disease, especially a cancer disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human.. . ... Novartis Ag

05/17/18 / #20180133147

Drug delivery systems

The present invention relates to thermogelling peptide delivery systems which are injected as fluid sol at ambient temperature through thin injection needles and transform into a highly viscous gel once inserted into human or animal body warm tissue. In a preferred embodiment said system is based on the use of a hydrophobic peptide, a chitosan and a glucose-phosphate.. ... Novartis Ag

05/17/18 / #20180133057

Medical instrument with an integrated optical fiber

In some embodiments, an illuminated microsurgical instrument system includes a microsurgical instrument having a distally projecting tubular member arranged to perform a medical procedure. The tubular member has a distal tip and an outer surface, the outer surface having a flat surface formed therein. ... Novartis Ag

05/17/18 / #20180132963

Medical instrument with an integrated optical fiber

Provided herein is an illuminated microsurgical instrument system and an illuminated microsurgical instrument. In one implementation, the system includes a microsurgical instrument having a distally projecting tubular member arranged to perform a medical procedure at an interventional site. ... Novartis Ag

05/17/18 / #20180132958

Tri-axial ergonomic footswitch

A foot-operated controller includes a base configured to rest on a floor surface, and a movable contact surface coupled to the base. The contact surface includes an anterior region to support a toe region and a posterior region to support a heel region, and is configured to roll about a roll axis in response to inversion or eversion of a foot engaged with the contact surface, pitch about a pitch axis in response to plantar flexion or dorsiflexion of the foot, and yaw about a yaw axis in response to abduction or adduction of the foot. ... Novartis Ag

05/17/18 / #20180132948

Ergonomic foot-operated joystick

A method and system provide a surgical system including a foot pedal and at least one pressure sensor. The foot pedal has a first axis and a second axis. ... Novartis Ag

05/10/18 / #20180129070

Convergence-sensing electro-active accommodating lens

. . . . A lens system comprises a first electro-active lens comprising a first focus sensor coupled to a first processor and a second electro-active lens comprising a second focus sensor coupled to a second processor. The first focus sensor periodically generates electromagnetic signals and detects electectromagnetic signals generated by the second focus sensor. ... Novartis Ag

05/10/18 / #20180127485

Fibronectin-based binding molecules and uses thereof

The invention provides fibronectin type iii (fn3)-based binding molecules that bind to a specific target antigen. The invention further provides bispecific fn3-based binding molecules that bind to two or more targets simultaneously. ... Novartis Ag

05/10/18 / #20180125996

Antibody drug conjugates

The present invention relates to anti-ckit antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.. . ... Novartis Ag

05/10/18 / #20180125853

Oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathy

The present invention relates to an oxazine derivative bace-1 inhibitor and pharmaceutical compositions comprising such oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathy and, in particular, wherein the patient carries one or two copies of the apoe4 allele.. . ... Novartis Ag

05/10/18 / #20180125820

Sacubitril-valsartan dosage regimen for treating heart failure

The present invention relates to sacubitril-valsartan dosage regimens for the treatment of heart failure in a patient.. . ... Novartis Ag

05/03/18 / #20180120590

Method for producing contact lenses with wearing comfort

The invention is related to a method for producing silicone hydrogel contact lenses with a stable lubricious hydrogel coating thereon providing a low surface friction. A method of the invention comprises forming a plasma-reactive hydrophilic polymer hybrid base coating having reactive functional groups on a silicone hydrogel contact lens and heating the silicone hydrogel contact lens with the hybrid base coating in an aqueous solution of a water-soluble and thermally crosslinkable hydrophilic polymeric material to form a stable lubricious hydrogel coating thereon.. ... Novartis Ag

05/03/18 / #20180120199

Contact lens inspection method and system

A method for determining the inversion state of a soft contact lens (1), comprising imaging a soft contact lens having a convex surface (2, 3) and a concave surface (3, 2), a lens center and a lens edge (5) surrounding said soft contact lens (1), the method comprising using an optical coherence tomography system to obtain at least one sectional image of at least a part of the contact lens (1) comprising the lens edge (5), determining a cross-sectional edge geometry of the contact lens (1) extending from the lens edge (5) towards the lens center of the contact lens in the sectional image, the cross-sectional edge geometry corresponding to the convex and concave surface boundaries of the contact lens (1) in the sectional image, selecting a parameter defining the cross-sectional edge geometry of the contact lens (1) imaged and comparing the parameter defining the cross-sectional edge geometry of the contact lens (1) with a predetermined parameter defining a cross-sectional edge geometry of a non-inverted contact lens to determine whether said contact lens (1) is inverted.. . ... Novartis Ag

05/03/18 / #20180118843

Silent fc variants of anti-cd40 antibodies

The present invention relates to silent fc variants of anti-cd40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.. . ... Novartis Ag

05/03/18 / #20180118678

Hemifumarate salt of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acid

This invention relates to a hemifumarate salt of 1-(4- 1-[(e)-cyclohexyl-3-tritluoromethy 1-benzy loxyimino ]-ethy 1)-2-ethy1-benzy l)-azetidine-3-carboxy lie acid (compound) to pharmaceutics compositions comprising this salt, to processes for forming this salt and to its use in medical treatment, addition, the present invention also relates to new polymorphic forms of the hemifumarate salt form of compound i, as well as to pharmaceutical compositions comprising these polymorphic forms, to processes for obtaining them, and their use in medical treatment.. . ... Novartis Ag

05/03/18 / #20180117059

Methods for treating egfr mutant cancers

Methods for the treatment of egfr mutated cancer. For example, treatment of non-small cell lung cancer (nsclc) with activating egfr mutations (e.g., l858r and ex19del) the acquired or resistant “gatekeeper” t790m mutation, or any combination of these mutations.. ... Novartis Ag

05/03/18 / #20180117011

Enzalutamide in combination with afuresertib for the treatment of cancer

A novel combination comprising an androgen receptor inhibitor, for example: 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide or a pharmaceutically acceptable salt thereof, and an akt inhibiting compound, for example: n-{(1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, and optional additional antineoplastic agents; pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which androgen receptor inhibition and/or akt inhibition is beneficial, e.g., cancer.. . ... Novartis Ag

05/03/18 / #20180117009

3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)

Disclosed are novel pharmaceutical compositions containing 3′-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazinol]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.. . ... Novartis Ag

04/19/18 / #20180106790

Single chain proteins with c-terminal modifications

The invention pertains to an isolated vh single domain antibody comprising a c-terminal modification, where the c-terminal modification comprises a deletion of at least one amino acid residue that eliminates the interaction of a pre-existing antibody with the single domain antibody without interfering with the binding of the single domain antibody with its target.. . ... Novartis Ag

04/19/18 / #20180105620

Hydrophilic copolymer with pendant thiol groups

The invention is related to a class of hydrophilic copolymers comprising loosely dangling thiol-containing pendant groups. The hydrophilic copolymers are highly reactive towards azetidinium groups of an azetidinium-containing polymer upon heating and can find particular use in for producing water-soluble highly-branched hydrophilic polymeric material useful for producing water gradient contact lenses.. ... Novartis Ag

04/19/18 / #20180105619

Hydrophilic copolymer with one thiol-containing terminal group

The invention is related to a class of hydrophilic polymers each comprising one sole thiol-containing terminal group. The hydrophilic polymers are highly reactive towards azetidinium groups of an azetidinium-containing polymer upon heating and can find particular use in for producing water-soluble highly-branched hydrophilic polymeric material useful for producing water gradient contact lenses.. ... Novartis Ag

04/19/18 / #20180104920

Method for producing contact lenses

The invention provides a method producing contact lenses, including the step of: holding the molded silicone hydrogel contact lens attached to the one of the female mold half or the male mold half with a vacuum supplied with a suction cup; deforming a surface of the one of the female mold half or the male mold half having the molded silicone hydrogel contact lens attached to with a pin so as to separate the molded silicone hydrogel contact lens from the mold half attached to and to transfer the molded silicone hydrogel contact lens to the suction cup; moving the suction cup away from the pin while the suction cup continues to hold the molded silicone hydrogel contact lens remains; applying a compressed gas to blow the molded silicone hydrogel contact lens away from the suction cup into a container.. . ... Novartis Ag

04/19/18 / #20180104919

Method for producing contact lenses

The invention provides a process for casting—molding contact lenses with enhanced quality and enhanced yield achieved by omitting the previously required check to discover on or in which mold half the contact lens is located after the mold has been opened. The process of the invention includes: providing a mold including a first mold half having a first molding surface and a second mold half having a second molding surface, wherein the first and second mold halves are configured to receive each other such that a mold cavity is formed between the first and second molding surfaces, wherein one of the first and second mold halves has a collar that encircles the other mold half to provide a seal between the two mold halves when the mold is closed; dispensing a polymerizable lens-forming material into one of the mold halves; mating the mold halves to close the mold; polymerizing the polymerizable material located between the two mold halves, thereby forming a molded contact lens; applying a force to non-optical surface of the female mold with a pin at a location about the center area of non-optical molding surface of the mold to deform the female mold thereby breaking the bonds between the optical molding surface of the female mold and the lens and opening the mold.. ... Novartis Ag

04/19/18 / #20180104388

Apparatus for controlling vacuum during ocular surgery

A method and system assist a physician in controlling pressure in a line during a surgery. The method includes filtering a vacuum signal such that portions of the vacuum signal having a frequency greater than a threshold frequency (e.g., ten hz) are not passed. ... Novartis Ag

04/19/18 / #20180104103

Internal shunt and method for treating glaucoma

A surgical technique and device wherein an indwelling tube is placed in the eye of a patient having glaucoma. The tube diverts aqueous humor from the anterior chamber to the suprachoroidal space from which it is removed by blood flowing in the choroidal and uveal tissues. ... Novartis Ag

04/19/18 / #20180104101

Formed cutter for vitrectomy probe

Vitreoretinal probes and methods related thereto are disclosed herein. A vitreoretinal probe may include a needle and a cutter slidably disposed within the needle. ... Novartis Ag

04/19/18 / #20180104100

Optical coherence tomography cross view imaging

An optical coherence tomography (oct) system and method for cross view imaging using at least two b-scan images transformed and coupled to each other at an angle to generate a cross view image.. . ... Novartis Ag

04/19/18 / #20180103972

Surgical instrument having a surface texture

Surgical instruments and, particularly, ophthalmic surgical instruments are disclosed. Example surgical instruments include forceps for removal of an internal limiting membrane (ilm). ... Novartis Ag

04/19/18 / #20180103844

Mechanical support of an indirect contact lens by a surgical microscope during vitreoretinal surgery

An indirect contact lens is mechanically coupled to a surgical microscope during ophthalmic surgery, such as vitreoretinal surgery. The indirect contact lens rests on a cornea of an eye of a patient during the surgery but is supported by a surgical microscope attachment having multiple degrees of freedom to accommodate small movements of the eye while remaining aligned to an optical axis of the surgical microscope.. ... Novartis Ag

04/19/18 / #20180103842

Scanning optical probe with flexing mechanism

A scanning optical probe and method includes a cannula, optical fiber, lens, and an actuating mechanism for tilting the optical fiber back and forth within the cannula. An actuator in the probe handle is coupled to various flexing and guide components extending through the cannula and towards the distal end of the scanning optical probe. ... Novartis Ag

04/12/18 / #20180100053

Chain-extended polydimethylsiloxane vinylic crosslinkers and uses thereof

The invention provides a chain-extended polydiorganosiloxane vinylic crosslinker which comprises (1) a polymer chain comprising at least two polydiorganosiloxane segments and one hydrophilized linker between each pair of polydiorganosiloxane segements, wherein each polydiorganosiloxane comprises at least 5 dimethylsiloxane units in a consecutive sequence, wherein the hydrophilized linker is a divalent radical having at least two (meth)acrylamide moieties; (2) two terminal (meth)acryloyl groups, wherein the chain-extended polydiorganosiloxane vinylic crosslinker has an average molecular weight of at least about 1500 daltons. The present invention is also related to a silicone hydrogel contact lens, which comprises repeating units derived from a chain-extended polydiorganosiloxane vinylic crosslinker of the invention. ... Novartis Ag

04/12/18 / #20180100038

Polymerizable polydimethylsiloxane-polyoxyalkylene block copolymers

The invention provides a polymerizable polydimethylsiloxane-polyoxyalkylene block copolymer which comprises (1) a linear polymer chain comprising at least two polydimethylsiloxane segments, one hydrophilic polyoxyalkylene segment between each pair of polydimethylsiloxane segments, and one amide-rich linker between each pair of one polydimethylsiloxane segment and one hydrophilic polyoxyalkylene segment, and (2) two terminal (meth)acryloyl groups. The hydrophilized polydiorganosiloxane vinylic crosslinker has a weight average molecular weight of at least 3000 daltons. ... Novartis Ag

04/12/18 / #20180098995

Combination products with tyrosine kinase inhibitors and their use

The present invention relates to pharmaceutical products comprising a combination of (i) a met inhibitor and (ii) an egfr inhibitor, or a pharmaceutically acceptable salt thereof, respectively, or a prodrug thereof, which are jointly active in the treatment of proliferative diseases, corresponding pharmaceutical formulations, uses, methods, processes, commercial packages and related invention embodiments.. . ... Novartis Ag

04/05/18 / #20180092775

Glaucoma treatment device

Methods and devices are adapted for implanting into the eye. An incision is formed in the cornea of the eye and a shunt is inserted through the incision into the anterior chamber of the eye. ... Novartis Ag

04/05/18 / #20180092702

Systems and methods for a surgical tissue manipulator

An apparatus for manipulating tissue during a procedure performed within an eye of a patient is disclosed herein. The apparatus includes a hand-held controller and an elongate member configured to be inserted into the eye of the patient. ... Novartis Ag

04/05/18 / #20180092524

Ocular modeling methods and apparatus

A method and apparatus for modelling a lens (104) of an eye (100), comprising: measuring (302) the anterior shape of the eye's cornea (102); determining (304) direct optical measurements of at least one parameter of the cornea (102) of the eye (100) and at least one parameter of the lens (104) of the eye (100); determining (306) the refractive index of the cornea; correcting (308) the optical measurements to account for the effect of the refractive index of the cornea on the direct optical measurements; measuring (310) the aberration of the eye; calculating (312) the refractive index of the lens by combining the corrected measurements and the aberration; and further correcting (314) the optical measurements of the lens to account the effect of the refractive index of the lens on the direct optical measurements.. . ... Novartis Ag

03/29/18 / #20180085362

Combination of phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor

. . . . . . The present invention relates to a pharmaceutical combination comprising a phosphatidylinositol-3-kinase (pi3k) inhibitor compound which is a 2-carboxamide cycloamino urea derivative or a pharmaceutically acceptable salt thereof and at least one mammalian target of rapamycin (mtor) inhibitor or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising such a combination; and the uses of such a combination in the treatment proliferative diseases, more specifically of mammalian target of rapamycin (mtor) kinase dependent diseases.. . ... Novartis Ag

03/29/18 / #20180085213

Heat tunable intraocular lens

A method and system provide an ophthalmic lens including a lens body having a chamber therein, a reservoir module coupled with the lens body and an optical fluid. At least part of the lens body is flexible. ... Novartis Ag

03/22/18 / #20180083621

Wireless ophthalmic surgical footswitch

. . Disclosed is a surgical footswitch, comprising a base, a pedal mounted to the base, and a variable air capacitor mechanically coupled to the pedal, such that movement of the pedal is operative to vary the capacitance of the variable air capacitor. The footswitch further comprises a capacitance-sensing controller circuit electrically connected to the variable air capacitor and configured to measure a capacitance of the variable air capacitor and to produce a control signal based on the measured capacitance, such that the control signal reflects a position of the pedal or a change in the position of the pedal, and a wireless interface electrically connected to the capacitance-sensing controller circuit and configured to wirelessly relay the control signal to a surgical console.. ... Novartis Ag

03/22/18 / #20180081197

Process for producing contact lenses with durable lubricious coatings thereon

The invention is related to a method for producing soft contact lenses comprises a silicone hydrogel lens body and a composite coating thereon. The composite coating comprises: a plasma base coating which is chemically-attached directly onto the surface of the silicone hydrogel contact lens and functions as a fail-proof measure for ensuring the hydrophobic silicone hydrogel lens material to be shielded from any exposure to ocular environments even after at least 30 days of daily uses including daily waring and daily cleaning/disinfecting; and a relatively-durable lubricious hydrogel top coating for ensuring wearing comfort. ... Novartis Ag

03/22/18 / #20180080046

Viral vectors for the treatment of retinal dystrophy

The present invention relates to viral vectors that are capable of delivering a heterologous gene to the retina and in particular delivering rlbp1 to rpe and müller cells of the retina. The invention also relates nucleic acids useful for producing viral vectors, compositions comprising the viral vectors and uses of the compositions and viral vectors. ... Novartis Ag

03/22/18 / #20180080013

Rna-guided gene editing system and uses thereof

The present invention provides rna-guided gene editing systems and methods of use thereof.. . ... Novartis Ag

03/22/18 / #20180079889

Method for producing a water-soluble thermally-crosslinkable polymeric material

The invention is related to a cost-effective method for producing water-soluble thermally-crosslinkable hydrophilic polymeric materials. Resultant materials can find particular use in preparing a packaging solution used for packaging and autoclaving medical devices, especially contact lenses. ... Novartis Ag

03/22/18 / #20180079799

Polyomavirus neutralizing antibodies

The present invention relates to anti-vp1 antibodies, antibody fragments, and their uses for the prevention and treatment of polyoma virus infection and associated diseases.. . ... Novartis Ag

03/22/18 / #20180079158

Hydrogel contact lenses with lubricious coating thereon

The invention is generally related to soft contact lenses which comprise a non-silicone hydrogel lens body and a hydrogel coating thereon. The non-silicone hydrogel lens body is composed of a hydrogel material which is free of silicone and comprises at least 50% by mole of repeating units of at least one hydroxyl-containing vinylic monomer. ... Novartis Ag

03/22/18 / #20180079157

Colored hydrogel contact lenses with lubricious coating thereon

The invention is generally related to colored contact lenses which comprise a hydrogel lens body having an opaque color image therein and/or thereon and a durable lubricious coating thereon. The coating comprises an anchoring layer of a polyanionic polymer having carboxyl groups and a hydrogel layer which is derived from a hydrophilic polymeric material having azetidinium groups and is covalently attached onto the anchoring layer of the polyanionic polymer through linkages each formed between one carboxyl group and one azetidinium groups. ... Novartis Ag

03/22/18 / #20180078540

Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor

The present invention relates to methods of treating or preventing a proliferative disease in a patient in need thereof by orally administering a therapeutically effective amount of an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor compound of formula (i) or a pharmaceutically acceptable salt thereof for at least two five-consecutive day cycle, wherein said compound is not administered to the patient for a period of about two days to about three days between said five-consecutive day cycles; the use of said compound of formula (i) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating or preventing a proliferative disease administered in accordance with said dosage regimen; therapeutic regimen comprising administration of said compound of formula (i) or a pharmaceutically acceptable salt thereof in accordance with said dosage regimen; and related pharmaceutical compositions and packages thereof.. . ... Novartis Ag

03/22/18 / #20180078315

Systems and methods for tracking the orientation of surgical tools

Methods, devices, and systems for determining an orientation of a surgical tool during ophthalmic surgery are disclosed. An example method includes performing an optical imaging scan in the surgical site, using a scan pattern that intersects the surgical tool and generating a scan image from the optical imaging scan. ... Novartis Ag

03/22/18 / #20180078130

Subtractive en face optical coherence tomography imaging

En face or 3d volumetric oct imaging during ophthalmic surgery may be performed with an oct scanning controller that interfaces to an oct scanner used with a surgical microscope. The oct scanner may generate en face images before and after surgical operations, such as retinal membrane peeling, are performed. ... Novartis Ag

03/15/18 / #20180071296

Combination therapy comprising an inhibitor of jak, cdk, and pim

. . . . The present invention relates to a pharmaceutical combination which comprises (a) a jak inhibitor compound, (b) a cdk inhibitor, and (c) a pim kinase inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of a myeloid neoplasm or leukemia; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of myeloid neoplasm or leukemia; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a mammal, especially a human.. . ... Novartis Ag

03/15/18 / #20180071251

Combination of lbh589 with other therapeutic agents for treating cancer

The invention relates to a combination comprising the n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2e-2-propenamide; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.. . ... Novartis Ag

03/15/18 / #20180071143

Ocular implant with stiffness qualities, methods of implantation and system

Described herein are devices and methods for treating eye conditions. Described is an ocular implant including an elongate member having an internal lumen forming a flow pathway, at least one inflow port communicating with the flow pathway, and at least one outflow port communicating with the flow pathway. ... Novartis Ag

03/08/18 / #20180066067

Antibodies and methods for wnt pathway-related diseases

. . . . The transmembrane e3 ubiquitin ligases znrf3 and rnf43 are negative regulators of β-catenin and the wnt signaling pathway in eukaryotic cells. The activity of znrf3 can be modulated by antibody binding to its extracellular domain, thus causing an increase in wnt signaling. ... Novartis Ag

03/08/18 / #20180066061

Methods of treating sporadic inclusion body myositis

The disclosure relates to the treatment of sporadic inclusion body myositis and other muscle wasting disorders with novel regimens, which employ a therapeutically effective amount of a myostatin antagonist, e.g., a myostatin binding molecule, e.g., a myostatin antibody or an actrii receptor binding molecule, an actrii receptor antibody, such as the bimagrumab antibody.. . ... Novartis Ag

03/01/18 / #20180062344

Ophthalmic illumination system with controlled chromaticity

. . An ophthalmic illumination system includes a broadband light source configured to emit a white laser beam, a first monochromatic light source configured to emit a first monochromatic laser beam having a first central wavelength, optics configured to receive a combined light beam comprising the white laser beam and the monochromatic laser, and a controller comprising a processor and a memory configured to control a chromaticity of the combined light beam by changing an output power of the first monochromatic light source.. . ... Novartis Ag

03/01/18 / #20180059436

Contact lens packaging solutions

The present invention relates to improved contact lens products which not only have an improved and sustainable wettability. The contact lens product of the invention comprises a soft hydrogel contact lens immersed and autoclaved in a packaging solution including a polyoxyethylene-polyoxybutylene block copolymer and a high molecular weight copolymer of n-vinylpyrrolidone and at least one amino-containing vinylic monomer. ... Novartis Ag

03/01/18 / #20180058627

Locking nut and washer

An articulated mechanism and associated systems and methods therefore are disclosed. An example articulating mechanism within the scope of the disclosure includes a stud, a keyed washer having a plurality of threaded apertures, and a nut. ... Novartis Ag

03/01/18 / #20180058438

Handheld ophthalmic probe with peristaltic pump and associated devices, systems, and methods

Systems, apparatuses, and methods of and for an ophthalmic surgical system are disclosed. An ophthalmic surgical system may include a handheld probe. ... Novartis Ag

03/01/18 / #20180057477

Heterocyclic compounds and methods for their use

The present invention relates to heterocyclic compounds useful for antagonising angiotensin ii type 2 (at2) receptor. More particularly the invention relates to compounds of formula (i), as described herein, compositions containing them and their cm use in methods of treating or preventing disorders or diseases associated with at2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.. ... Novartis Ag

03/01/18 / #20180057457

Chemical process for preparing pyrimidine derivatives and intermediates thereof

The present disclosure relates to a method of synthesizing 5-chloro-n2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine (ceritinib) and/or intermediates thereof, their use as pharmaceuticals and pharmaceutical compositions and the use of intermediates for preparing ceritinib.. . ... Novartis Ag

03/01/18 / #20180056613

Process for dispensing a contact lens forming fluid material

A method for dispensing a material into a mold for forming contact lenses, comprises the steps of: (1) providing a contact lens mold, (2) providing a dispensing needle, wherein the dispensing needle is made from a material having a surface energy less than 32 dynes/cm, (3) arranging the contact lens mold underneath the dispensing needle, (4) dispersing a fluid composition into a mold for making a contact lens, wherein the fluid composition comprises a lens-forming material, and the lens-forming material containing a solvent and is crosslinkable and/or polymerizable by thermal curing or actinic radiation.. . ... Novartis Ag

03/01/18 / #20180055769

Circulation of components during microfluidization and/or homogenization of emulsions

An improved method for the manufacture of an oil-in-water emulsion involves circulation of emulsion components between a first container and a second container via a homogenizer and/or via a microfluidization device. Usefully, all of the emulsion components from the first container are emptied before being returned.. ... Novartis Ag

03/01/18 / #20180055688

Systems and methods for non-invasive measurement of cassette pressure

A method and system provide a surgical system including a cassette, a console and an interferometric pressure sensing system coupled with the console. The cassette is for exchanging material with a patient and includes a wall and a reflector. ... Novartis Ag

03/01/18 / #20180055596

Planar illuminator for ophthalmic surgery

The present disclosure provides illumination apparatus for ophthalmic surgery comprising a light that provides planar field illumination, as well as methods of using the illumination apparatus. The illuminators of the present disclosure can be used in intraocular refractive and vitroretinal surgery to better enable visualization of anatomical structures of the eye currently difficult to view, capturing detail that would normally be obscured using conventional illumination apparatus.. ... Novartis Ag

03/01/18 / #20180055592

Surgical probe with an integrated motion sensor

A surgical probe system comprising a surgical probe having an instrument tip, and at least one motion sensor located within the surgical probe that measures movement and orientation data. The system further includes a processor that is configured to determine movement and orientation of the instrument tip based on the movement and orientation data, and adjust at least one surgical parameter of the surgical probe based on the movement and orientation of the instrument tip to affect a predetermined surgical outcome.. ... Novartis Ag

03/01/18 / #20180055581

Predictive apparatus for assisting a physician during ophthalmic surgery

A method and system assist a physician in performing an ophthalmic surgery. The method includes receiving a quasi-real time image of at least a first portion of the eye. ... Novartis Ag

02/22/18 / #20180051092

Methods of treatment by administering an anti-baffr antibody therapeutic formulation

. . Anti-baffr antibodies are formulated as liquid formulation comprising a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The aqueous pharmaceutical composition may include one or more sugars, a buffering agent, a surfactant, and/or a free amino acid.. ... Novartis Ag

02/22/18 / #20180049921

Phacoemulsification hand piece with integrated aspiration pump

An ophthalmic surgical hand piece comprises a driver coupled to a horn. The horn is coupled to a needle. ... Novartis Ag

02/22/18 / #20180049920

Surgical apparatus including aspiration device sensors

A method and system provide a surgical hand piece including an aspiration line, a tip and a sensor. The tip is coupled with the aspiration line. ... Novartis Ag

02/22/18 / #20180049919

Articulating ophthalmic surgical probe

An articulating optical surgical probe includes a handle sized to fit in a single hand and a single rigid cannula extending from the handle having a diameter of 20 ga or less. The probe further includes a slotted tip at a distal end of the cannula and at least one optical fiber extending through the handle, the single rigid cannula and the slotted tip, and a pull-wire secured to the slotted tip. ... Novartis Ag

02/22/18 / #20180049866

Systems and methods for deployment damping in intraocular lens deployment

Intraocular lens (iol) insertion apparatus and methods of use are provided and described herein. An example iol insertion apparatus may include a handpiece body having a distal tip, a deployment chamber having an opening at a distal end of the handpiece body, and a deployment system disposed within the handpiece body. ... Novartis Ag

02/22/18 / #20180049865

Synthetic flap for trabeculectomy procedures

A method includes forming a conjunctival incision in a patient's eye, attaching a synthetic flap to the patient's eye within the conjunctival incision, forming a scleral tunnel underneath the synthetic flap, the scleral tunnel extending from an exterior of a sclera to an anterior chamber of the patient's eye, and closing the conjunctival incision.. . ... Novartis Ag

02/22/18 / #20180049864

Devices, systems, and methods for trabecular meshwork extension

Described herein is an extension device to extend ocular tissue within an irideocorneal angle of an eye of a patient, comprising a flexible body and a plurality of tensioning features disposed on the body. The body is sized and configured to be disposed within the irideocorneal angle. ... Novartis Ag

02/15/18 / #20180045927

Surgical microscope with integrated optical coherence tomography and display systems

An ophthalmic surgical microscope includes a beam coupler positioned along an optical path of the surgical microscope between a first eyepiece and magnifying/focusing optics, the beam coupler operable to direct the oct imaging beam along a first portion of the optical path of the surgical microscope between the beam coupler and a patient's eye (an oct image being generated based on a reflected portion of the oct imaging beam). The surgical microscope additionally includes a real-time data projection unit operable to project the oct image generated by the oct system and a beam splitter positioned along the optical path of the surgical microscope between a second eyepiece and the magnifying/focusing optics. ... Novartis Ag

02/15/18 / #20180044549

Silicone hydrogel lenses with water-rich surfaces

The invention is related to a hydrated silicone hydrogel contact lens having a layered structural configuration: a lower water content silicone hydrogel core (or bulk material) completely covered with a layer of a higher water content hydrogel totally or substantially free of silicone. A hydrated silicone hydrogel contact lens of the invention possesses high oxygen permeability for maintaining the corneal health and a soft, water-rich, lubricious surface for wearing comfort.. ... Novartis Ag

02/15/18 / #20180044410

Angiopoietin-like 4 antibodies and methods of use

The present invention relates to monoclonal antibodies binding to human angiopoietin-like 4 protein (hereinafter, sometimes referred to as “angptl4”), and pharmaceutical compositions and methods of treatment comprising the same.. . ... Novartis Ag

02/15/18 / #20180042895

Treatment of autoimmune disease in a patient receiving additionally a beta-blocker

The present invention relates to methods of treating autoimmune diseases with siponimod in patients receiving additionally a beta-blocker.. . ... Novartis Ag








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Novartis Ag in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Novartis Ag with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###